Neogen appoints Doug Jones as COO; VP Genomics Marylinn Munson departs

NEOGEN CORP

Doug Jones named Chief Operating Officer, a newly created role overseeing worldwide revenues and operations.
Dr. Jason Lilly assumes interim responsibility for North American genomics operations.
Marylinn Munson, former Vice President of Genomics, has left the company.
Jerome Hagedorn (VP North American Operations) and Dr. Lilly will report to Jones; Jones reports to CEO John Adent.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Doug Jones

Chief Operating Officer

NEOG · NEOGEN CORP

Effective: 2022-04-19
Filed: April 21, 2022, 7:59 PM ET

On April 19, 2022, Neogen Corporation (the “Registrant”) announced that Doug Jones was named Chief Operating Officer.

Departed

Marylinn Munson

Vice President, Genomics

NEOG · NEOGEN CORP

Filed: April 21, 2022, 7:59 PM ET

Marylinn Munson, former Vice President, Genomics, has left the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Doug Jones was named as Chief Operating Officer at NEOGEN CORP.

Action: named
Role: Chief Operating Officer

Exact text from the filing

On April 19, 2022, Neogen Corporation (the “Registrant”) announced that Doug Jones was named Chief Operating Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Marylinn Munson departed as Vice President, Genomics at NEOGEN CORP.

Action: left
Role: Vice President, Genomics

Exact text from the filing

Marylinn Munson, former Vice President, Genomics, has left the Company.

View on SEC.gov

NEOGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-22-113159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.